Author

A. Nam

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4 Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Assay:bulk RNA-seq· 3 Approach:experimental assay· 3 Approach:statistical model· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

P. Kulkarni· 4 shared R. Salgia· 4 shared A. Mohanty· 3 shared A. Nathan· 3 shared I. Mambetsariev· 3 shared M. K. Jolly· 3 shared E. Massarelli· 2 shared L. Yang· 2 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

P. Kulkarni

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Spatial transcriptome profiling of in vitro 3D tumouroids to study tumour-stroma interactions

D. Bakkalci, G. Al-Badri, W. Yang, A. Nam, Y. Ling, S. A. Khurram, S. Heavey, S. Fedele, U. Cheema

This study uses spatial transcriptomics to analyze how different stromal cells affect gene expression and behavior in engineered ameloblastoma tumouroids.

bioRxiv · Dec 13, 2022 · PreprintBioengineering

The Ephrin receptor A2 and Roundabout Guidance Receptor 1 heterodimer: A potential theranostic for squamous cell carcinomas

K. M. Pang, S. Srivastava, M. Iida, M. Nelson, J. Liu, A. Nam, J. Wang, I. Mambetsariev, A. Mohanty, N. McDaniel, A. Behal, P. Kulkarni, D. L. Wheeler, R. Salgia

The paper shows that the EPHA2-ROBO1 heterodimer reduces growth of lung and head and neck squamous cell carcinomas and suggests SLIT2 and Ensartinib as potential therapies.

bioRxiv · Apr 9, 2020 · PreprintCancer Biology

Suppressing chemoresistance in lung cancer via dynamic phenotypic switching and intermittent therapy

A. Nam, A. Mohanty, S. Bhattacharya, S. Kotnala, S. Achuthan, K. Hari, A. Nathan, G. Rangarajan, E. Massarelli, H. Levine, M. K. Jolly, P. Kulkarni, R. Salgia

This study shows that intermittent chemotherapy can suppress chemoresistance in lung cancer by preventing the emergence of tolerant cells through dynamic phenotypic switching.

bioRxiv · Apr 6, 2020Cancer Biology

A Non-genetic Mechanism for Chemoresistance in Lung Cancer: The Role of Integrin β4/Paxillin Axis

A. Mohanty, A. Nam, A. Pozhitkov, S. Bhattacharya, L. Yang, A. Nathan, X. Wu, S. Srivastava, I. Mambetsariev, M. Nelson, R. Pangeni, D. Raz, Y. Chen, Y. He, J. Orban, , R. Salgia

This study identifies a non-genetic mechanism for cisplatin resistance in lung adenocarcinoma involving the integrin β4/paxillin axis and its regulation of USP1 and VDAC1.

bioRxiv · Sep 25, 2019Cancer Biology

Phenotypic Switching of Naïve T cells to Immune-suppressive Treg-like Cells by Mutant KRAS

A. Kalvala, P. Wallet, L. Yang, C. Wang, H. Li, A. Nam, A. Nathan, I. Mambetsariev, V. Poroyko, H. Gao, P. Chu, M. Sattler, A. Bild, E. R. Manuel, P. P. Lee, , R. Salgia

The paper shows mutant KRAS induces T cells to become immune-suppressive Treg-like cells through exosomes, sera, or direct transfection, with single-cell sequencing identifying the interferon pathway as the mechanism.

bioRxiv · Sep 11, 2019Cancer Biology